Human papillomavirus vaccination: Component of an integrated HIV prevention program?

AIDS

Volumn 26, Issue 17, 2012, Pages 2251-2252

  Schim Van Der Loeff, Maarten F ^a,b   Giuliano, Anna R ^c  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

HIV; human papillomavirus; meta analysis; randomized clinical trial; vaccine

Indexed keywords

WART VIRUS VACCINE;

CIRCUMCISION; DISEASE PREDISPOSITION; DRUG EFFICACY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; SEXUAL BEHAVIOR;

EID: 84869390681     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328359ab44     Document Type: Note

References (13)

1. Houlihan CF, Larke NL, Watson-Jones D, Smith-McCune KK, Shiboski S, Gravitt PE, et al. HPV infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS 2012; 26:2211-2222.
2. Schim van der Loeff MF, Nyitray AG, Giuliano AR. HPV vaccination to prevent HIV infection: time for randomized controlled trials. Sex Transm Dis 2011; 38:640-643.
3. GAVI Alliance. www.gavialliance.org. [Accessed 3 August 2012].
4. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26 (Suppl 10):K17-K28; Review.
5. WHO/IARC. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. WHO: Lyon, 2007. pp. 1-180.
6. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120-1130.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al., CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
8. FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection. FD News Release. 16 July 2012. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm312210.htm. [Accessed 1 August 2012].
9. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. The Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
10. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al., HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
11. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. The FEM-PrEP Study Group. Preexposure prophylaxis for HIV Infection among African women. N Engl J Med 2012; 367:411-422.
12. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272-279; Review.
13. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al., CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-1451.